Recent studies suggest Pepto Bismol may not effectively prevent traveler's diarrhea.

A 2025 CDC-led study found no significant difference in diarrhea incidence between travelers taking bismuth subsalicylate and those on placebo. While Pepto Bismol remains approved for treating diarrhea, its preventive use for traveler's diarrhea might be less effective than previously believed.